A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Baclofen (FLEQSUVY)

INDICATIONS AND USAGE Baclofen tablets, USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and co....

First FDA approval1988-07-21
Generic availableYes · 21 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$134.2M in CY2024 Part D spend7.8M claims · 2.4M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.033/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.033
Across all dosage forms in distribution.
Highest NADAC
$0.033
Range is tight.
Plans with PA
1 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Baclofen used for?

INDICATIONS AND USAGE Baclofen tablets, USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and co....

Is there a generic for Baclofen?

Yes. 65 ANDAs filed at FDA, 21 generic manufacturers currently shipping.

How much does my plan pay for Baclofen?

Across 329 Part D plans, Baclofen averages $0.033/unit (NADAC). Lowest available: $0.033/unit. Highest in distribution: $0.033/unit.

Is Baclofen on the FDA shortage list?

Baclofen has been discontinued by its manufacturer(s).

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

gamma-Aminobutyric Acid-ergic Agonist1 alternative in D1
01
Baclofen Injection
Brand: Gablofen
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.